Alpha Cognition将于2025年10月23日至25日在美国顾问药剂师协会年会上展示关于胆碱酯酶抑制剂和ZUNVEYL的新临床见解，并于2025年11月6日至9日在神经科学教育研究所年会上展示

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of Consultant Pharmacists (ASCP) Annual Meeting (October 23–25, 2025) and the Neuroscience Education Institute (NEI) Annual Congress (November 6–9, 2025).The Company's accepted poster presentations include:

ASCP Annual Meeting

• Poster 12: Acetylcholinesterase Inhibitors and Psychotropic Medication Use in Alzheimer's Disease and Related Dementias (ADRD)
• Poster 3: Acetylcholinesterase Inhibitor Persistence: The Value of Sustained Therapy in Alzheimer's Disease and Related Dementias
• Poster 4: Evidence-Based Methodologies for Switching Between AChEIs in Alzheimer's Disease: A Review

NEI Annual Congress

• Poster 11: Literature Review: Acetylcholinesterase Inhibitors and Effects on Mortality in Alzheimer's Disease and Related Dementias
• Poster 12: Literature Review: Acetylcholinesterase Inhibitors and Effects on Sleep in Alzheimer's Disease

It has been more than a decade since the last cholinesterase inhibitor came off patent, and during that time, these agents have faded from clinical focus," said Dr. Denis Kay, Chief Scientific Officer at Alpha Cognition. "It is important to reintroduce the well-established role of these medications in the treatment of Alzheimer's disease (AD). Unless contraindicated, most AD patients should receive these treatments as first-line therapy. The recent introduction of the enteric-coated prodrug ZUNVEYL (benzgalantamine) provides cholinesterase inhibition and nicotinic acetylcholine receptor modulation in a novel formulation designed to address prior challenges in treatment continuity."